Compare · CLNN vs JNJ
CLNN vs JNJ
Side-by-side comparison of Clene Inc. (CLNN) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CLNN and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $610.38B, about 12993.1x CLNN ($47.0M).
- JNJ has been more active in the news (16 items in the past 4 weeks vs 3 for CLNN).
- JNJ has more recent analyst coverage (25 ratings vs 4 for CLNN).
- Company
- Clene Inc.
- Johnson & Johnson
- Price
- -
- -
- Market cap
- $47.0M
- $610.38B
- 1M return
- -25.66%
- -
- 1Y return
- -65.27%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 3
- 16
- Recent ratings
- 4
- 25
Clene Inc.
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean surfaced nanotechnology (CSN) therapeutics. The company has a nanotechnology drug suspension; and engages in the development and commercialization of dietary supplements. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2 study for the treatment of stable multiple sclerosis; a Phase 2 biomarker study in Parkinson's; and Phase 2 and Phase 3 trials to investigate the potential for disease modification for neurodegenerative diseases. The company's products also include CNM-AgZn17, a topical gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat disease-causing infections, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. Clene Inc. is headquartered in Salt Lake City, Utah.
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest CLNN
- Amendment: SEC Form SCHEDULE 13G/A filed by Clene Inc.
- Clene to Present at Upcoming Investor Conferences
- Clene Announces Closing of $4 Million Registered Direct Offering Extending Capital Runway Beyond FDA Decision on CNM-Au8® NDA
- Director Matlin David J was granted 434,451 shares (SEC Form 4)
- President & CEO Etherington Robert Dee was granted 15,244 shares (SEC Form 4)
- Director Mosca Alison was granted 198,171 shares (SEC Form 4)
- Clene Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by Clene Inc.
- Clene Announces $4 Million Registered Direct Offering
- A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach
Latest JNJ
- SEC Form 8-K filed by Johnson & Johnson
- Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2026
- Johnson & Johnson reports Q3 2026 results, raises 2026 guidance
- TREMFYA® (guselkumab) demonstrated sustained clinical and endoscopic remission through 3 years in moderately to severely active Crohn's disease
- New TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key Crohn's disease patient subgroups
- After a Record-Setting Week, Wall Street Turns to Inflation Data and the First Big Earnings Reports
- New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis
- 2026 Takes a Promising Turn in the Fight Against Cancer as Five Advances Offer New Hope
- Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy
- New Global Survey by Johnson & Johnson Finds Most Women Don’t Connect Eye Health Changes with Menopause